✦ LIBER ✦

Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

✍ Scribed by Andrew G. Bostom; Myra A. Carpenter; Lawrence Hunsicker; Paul F. Jacques; John W. Kusek; Andrew S. Levey; Joyce L. McKenney; Renee Y. Mercier; Marc A. Pfeffer; Jacob Selhub

Book ID: 114468843
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 283 KB
Volume: 53
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2008.08.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design of the Folic Acid f

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial

✍ Andrew G. Bostom; Myra A. Carpenter; John W. Kusek; Lawrence G. Hunsicker; Marc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 117 KB

52 Prevalence of CVD Risk Factors and th

52 Prevalence of CVD Risk Factors and their Treatment in Chronic, Stable Kidney Transplant Recipients in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

✍ Myra A. Carpenter; Andrew Bostom; John W. Kusek; Deborah Adey; Edward Cole; Andr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Baseline characteristics of participants

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

✍ Nanette Kass Wenger; Elizabeth Barrett-Connor; Peter Collins; Deborah Grady; Mar 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Baseline characteristics of the patient

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

✍ Mosenzon, O.; Raz, I.; Scirica, B. M.; Hirshberg, B.; Stahre, C. I.; Steg, P. G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

Rationale, design and baseline character

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial

✍ Eva Lonn 📂 Article 📅 2006 🏛 Pulsus Group Inc 🌐 English ⚖ 237 KB

Rationale, design, and baseline characte

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

✍ The ORIGIN Trial Investigators 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 188 KB